SVB Securities analyst Mani Foroohar reiterated a Hold rating on Bluebird Bio (BLUE – Research Report) yesterday and set a price target of $8.00. The company's shares closed last Tuesday at $3.85, close to its 52-week low of $3.30. According to TipRanks.com, Foroohar 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -26.3% and a 30.9% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and 4D Molecular Therapeutics. Currently, the analyst consensus on Bluebird Bio is a Hold with an average price target of $6.83, representing an 80.2% upside.
https://www.tipranks.com/news/blurbs/bluebird-bio-blue-receives-a-hold-from-svb-securities?utm_source=advfn.com&utm_medium=referral
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more bluebird bio Charts.
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more bluebird bio Charts.